Key Takeaway: Telix has released a clinical data summary for TLX591-Tx, a PSMA-targeted radio antibody-drug conjugate aimed at treating metastatic castration-resistant prostate cancer. The summary includes dosimetry, safety, and efficacy data from the ProstACT SELECT Phase 1 study and outlines the ongoing ProstACT GLOBAL Phase 3 trial. TLX591-Tx has not yet received marketing authorization.
Price reaction · baseline $7.52 (2026-02-26 close) · hit pre-market · 2 other TLX headline(s) in the window, move may be shared
day 0 close · peak
-3.6%
Market Sentiment Analysis
POSITIVE FACTORS
TLX591-Tx shows promising safety and efficacy data.
The ongoing Phase 3 trial aims to further validate its effectiveness.
The drug targets metastatic castration-resistant prostate cancer, a significant need.
CONCERNS & RISKS
TLX591-Tx has not yet received marketing authorization.
The drug is still in the trial phase and may face regulatory hurdles.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease
Full Press Release Details
27 February 2026
As a resource for analysts and investors, Telix has published a clinical data summary for TLX591-Tx (lutetium-177 rosopatamab tetraxetan), its investigational PSMA-targeted radio antibody-drug conjugate (rADC) for metastatic castration-resistant prostate cancer (mCRPC). The summary covers established dosimetry, safety, and efficacy data from the ProstACT SELECT Phase 1 study and prior clinical studies, as well as the design of the ongoing ProstACT GLOBAL Phase 3 trial.
View the full clinical data summary here
TLX591-TX has not received a marketing authorization in any jurisdiction.
Frequently Asked Questions
What is TLX591-Tx?
TLX591-Tx is an investigational PSMA-targeted radio antibody-drug conjugate for mCRPC.
What studies are included in the TLX591-Tx summary?
The summary includes data from the ProstACT SELECT Phase 1 study and prior clinical studies.
What is the status of TLX591-Tx's marketing authorization?
TLX591-Tx has not received marketing authorization in any jurisdiction.
What trial is currently ongoing for TLX591-Tx?
The ongoing trial is the ProstACT GLOBAL Phase 3 trial.